MARKET

SYNH

SYNH

SYNEOS HEALTH
NASDAQ

Real-time Quotes | Nasdaq Last Sale

59.30
-0.40
-0.67%
Closed 18:12 10/20 EDT
OPEN
60.18
PREV CLOSE
59.70
HIGH
60.75
LOW
59.01
VOLUME
564.40K
TURNOVER
--
52 WEEK HIGH
74.25
52 WEEK LOW
30.02
MARKET CAP
6.20B
P/E (TTM)
33.31
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Syneos Health Named to Forbes 2020 List of World’s Best Employers
Company Ranks Highest Among Biopharmaceutical Outsourcing OrganizationsMORRISVILLE, N.C., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the Company has been named to the Forbes 2020 list of World’s Best Employers, ranking highest among biopharmaceutical outsourcing organizations. This recognition is realized just three years into the Company’s journey to create a leading insights-driven product development organization fueled by top talent and a collaborative culture. At Syneos Health employees work across clinical and commercial disciplines in sync, sharing data, insights and knowledge to deliver innovative, integrated solutions that change patients' lives. Syneos Health employs 24,000 people servicing biopharmaceutical companies in more than 110 countries who are dedicated to shortening the distance from lab to life®.“From day one, we aimed to create a new kind of Company – one with a transformative business model and a unique empowering culture to match. We looked to create an inclusive environment where bringing your authentic self to work is the norm and strategic problem solvers with a passion for accelerating the delivery of medicines to patients thrive,” said Alistair Macdonald, Chief Executive Officer, Syneos Health. “Thank you to our global workforce for the important life-changing work you do each day, and for the critical role you play in co-creating our culture.”The Company lives three fundamental Values including Challenge the Status Quo, Collaborate to Deliver Solutions and Passionate to Change Lives – all critical to delivering seamless product solutions. Employees are also provided continuous learning experiences as part of the organization’s Biopharmaceutical Acceleration Academy, including award-winning leadership and development programs and accreditation trainings.“This recognition is significant and a true moment of pride and reflection about how our employees feel about the Company we’re building together,” commented Lisa van Capelle, Chief Human Resources Officer, Syneos Health. “At Syneos Health we are committed to listening and learning from each other, hyper-collaboration and bringing our Total Selves to work where we support the emotional, physical and community wellbeing of our employees. We’re constantly looking for top talent who wants to help chart our next chapter.”Forbes and Statista Inc., the world-leading statistic portal and industry ranking provider, selected companies for the World’s Best Employers list based on anonymous independent surveys of more 160,000 employees in more than 58 countries. Participants were asked to rate their employers as well as other employers in the industry on topics such as gender equality, social responsibility, image, economic footprint, talent development and COVID-19 response. Over 5,000,000 data points were analyzed.View our Career Openings and Get to Know Our People and Culture * Learn about career opportunities at Syneos Health – including clinical, commercial and corporate careers, in rapidly growing areas such as oncology. * Follow us on LinkedIn to view our weekly Resilient Together video series, highlighting how our employees have adapted together during the pandemic to continue to deliver impact for our customers and patients.   * View our People with Purpose video series which shows what makes our colleagues tick and how it influences the important work we do each day to impact patient lives.About Syneos Health Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Our Company brings together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com.Syneos Health Investor Relations Contact: Ronnie Speight Senior Vice President, Investor Relations +1 919 745 2745 investor.relations@syneoshealth.com   Syneos Health Press/Media Contact: Danielle DeForge Vice President, External Communications +1 202 210 5992 danielle.deforge@syneoshealth.com
GlobeNewswire · 1d ago
Syneos Health Wins Society for Clinical Research Sites Eagle Award for Fourth Consecutive Year
MORRISVILLE, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it was awarded the Society for Clinical Research Sites (SCRS) Eagle Award, sweeping the CRO category for the fourth consecutive year. Presented at SCRS’s Global Site Solutions Summit, the award recognizes the CRO that best exemplifies a site-focused approach to clinical trial management, demonstrating outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships. “We are honored that sites have consistently selected Syneos Health as their CRO of choice in recent years, pointing to the progress we’ve made in streamlining pain points in the clinical trial process,” said Tara Fitzgerald, President, Clinical Development Services, Syneos Health, who accepted the award on behalf of the company at the Summit. “It’s especially humbling in a year where we’ve been proud to work side-by-side with sites to navigate the challenges of COVID-19, transforming approaches to deliver impact for patients and continuing to unlock data to change lives. We thank our dedicated employees and the investigative sites we work with who continuously strive to improve the clinical development process.”This year’s winners were selected by investigative sites – nearly 10,000 research sites in 47 countries – who voted for the CRO they believe best demonstrates a strong commitment to site partnerships. Selection criteria included availability of qualified staff to support sites, willingness to collaborate, protocol design and execution, financial consideration and partnering with sites for future work.“Syneos Health has won the SCRS Eagle Award for three previous years in the CRO category, and this fourth win is in a very different landscape," said Allyson Small, SCRS COO. "The pandemic disruption stretched operational systems in clinical research, making relationships critically important, with the sites recognizing Syneos Health in particular for their prioritization of the site partnership."  Learn more about Syneos Heath’s site and patient engagement programs, including the Company’s Catalyst Site Program that delivers proven predictability in clinical trial delivery for for Early Phase, Oncology, Psychiatry, Vaccine, Ophthalmology and Post-Operative Pain and Pain trials: syneoshealth.com/catalystAbout Syneos Health Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com or subscribe to our podcast.Investor Relations Contact:  Press/Media Contact: Ronnie Speight   Danielle DeForge Senior Vice President, Investor Relations Vice President, External Communications +1 919 745 2745 +1 202 210 5992 Investor.Relations@syneoshealth.com  danielle.deforge@syneoshealth.com
GlobeNewswire · 10/13 13:45
Is Syneos Health, Inc. (NASDAQ:SYNH) Potentially Undervalued?
While Syneos Health, Inc. (NASDAQ:SYNH) might not be the most widely known stock at the moment, it saw a double-digit...
Simply Wall St. · 10/07 16:45
Syneos Health upgraded to buy from neutral at Mizuho
SYNH | Complete Syneos Health Inc. Cl A stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 10/06 09:58
Syneos Health Schedules Third Quarter 2020 Earnings Call for Thursday, October 29, 2020
MORRISVILLE, N.C., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2020 financial results on Thursday, October 29, 2020, prior to its earnings call at 8:00 a.m. ET. Participants may access
GlobeNewswire · 10/05 21:58
Syneos Health ticks higher on 'Buy' rating from Goldman Sachs
Biopharmaceutical solutions organization, Syneos Health ([[SYNH]] +5.4%) has been upgraded to Buy from Neutral at Goldman Sachs with a price target of $75 (33% upside), up from $69.According to analyst,
Seekingalpha · 10/01 19:22
Goldman Sachs Upgrades Syneos Health to Buy, Raises Price Target to $75
Goldman Sachs analyst Robert Jones upgrades Syneos Health (NASDAQ:SYNH) from Neutral to Buy and raises the price target from $69 to $75.
Benzinga · 10/01 11:05
Syneos Health Banks on Essential Therapies Amid Coronavirus Woe
Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.
Zacks · 09/28 13:59
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYNH. Analyze the recent business situations of SYNEOS HEALTH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYNH stock price target is 73.62 with a high estimate of 83.00 and a low estimate of 65.00.
EPS
Institutional Holdings
Institutions: 394
Institutional Holdings: 134.49M
% Owned: 128.73%
Shares Outstanding: 104.47M
TypeInstitutionsShares
Increased
83
5.00M
New
91
1.91M
Decreased
114
7.48M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Independent Director
John Dineen
Chief Executive Officer/Director
Alistair Macdonald
Chief Financial Officer
Jason Meggs
Corporate Executive
Paul Colvin
Corporate Executive
Michelle Keefe
Chief Human Resource Officer
Lisa van Capelle
Director
Tom Allen
Executive Vice President/Chief Accounting Officer
Robert Parks
General Counsel/Secretary
Jonathan Olefson
Independent Director
Todd Abbrecht
Independent Director
Thomas Allen
Independent Director
Bernadette Connaughton
Independent Director
Linda Harty
Independent Director
William Klitgaard
Independent Director
John Maldonado
Independent Director
Kenneth Meyers
Independent Director
Matthew Monaghan
Independent Director
Joshua Nelson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SYNH
Syneos Health Inc. is a fully integrated biopharmaceutical solutions providing company. The Company offers both stand-alone and integrated biopharmaceutical product development solutions through its Contract Research Organization (CRO) and Contract Commercial Organization (CCO), ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. It brings together approximately 24,000 clinical and commercial professionals with the ability to support customers in more than 110 countries. Together it shares insights, leverages latest technologies and apply advanced business practices to deliver important therapies to patients.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Syneos Health Inc stock information, including NASDAQ:SYNH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYNH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYNH stock methods without spending real money on the virtual paper trading platform.